DelveInsight's "CABLIVI Market Size, Forecast, and Market Insight Report" highlights the details around CABLIVI, a von ...

Additionally, danaparoid, argatroban, and lepirudin are approved for treating thrombosis in patients with heparin-induced thrombocytopenia. For severe thrombocytopenia related to chronic liver ...

Developed by Sanofi, CABLIVI is the first FDA-approved nanobody therapy for this condition. Increasing awareness, improved diagnostic rates, and rising demand for targeted therapies in hematology ...

This small study demonstrated a high incidence of antibody development possibly associated with the long-term exposure to lepirudin; however, no adverse effects were associated with antibody ...

Dysfibrinogen Kagoshima with the amino acid substitution gammaThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule.

1 Department of Anesthesiology and Intensive Care Medicine, Hannover Medical School, Hannover, Germany 2 Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine and University ...